Davenport & Co’s Axsome Therapeutics AXSM Stock Holding History

Davenport & Co’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$332K	Hold	1,800	–	–	﹤0.01%	1156
2026 Q2	$441K	Hold	1,800	–	–	﹤0.01%	1066
2026 Q1	$304K	Hold	1,800	–	–	﹤0.01%	1126
2025 Q4	$329K	Sell	1,800 -67	-4%	-$9.35K	﹤0.01%	1053
2025 Q3	$227K	Buy	+1,867	New	+$210K	﹤0.01%	1167
2025 Q2	–	Sell	-1,867	Closed	-$218K	–	1209
2025 Q1	$218K	Buy	+1,867	New	+$213K	﹤0.01%	1109
2024 Q2	–	Sell	-5,817	Closed	-$464K	–	1115
2024 Q1	$464K	Buy	5,817 +2,000	+52%	+$168K	﹤0.01%	833
2023 Q4	$304K	Buy	+3,817	New	+$255K	﹤0.01%	907
2023 Q1	–	Sell	-14,200	Closed	-$1.1M	–	1045
2022 Q4	$1.1M	Buy	+14,200	New	+$849K	0.01%	484
2020 Q1	–	Sell	-2,300	Closed	-$238K	–	669
2019 Q4	$238K	Buy	+2,300	New	+$92.9K	﹤0.01%	636

Other funds holding AXSM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Davenport & Co's AXSM Position: Q3 2026 in Review

Davenport & Co held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 1,800 shares worth $332K. The position accounts for ﹤0.01% of the portfolio, ranked #1156.

Davenport & Co first reported a position in AXSM in Q4 2019 and has held it in 10 quarters since. The position peaked at $1.1M in Q4 2022. 185 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Davenport & Co held 1,800 shares of Axsome Therapeutics worth $332K as of Q3 2026.
Davenport & Co left its Axsome Therapeutics share count unchanged in Q3 2026.
Axsome Therapeutics made up ﹤0.01% of Davenport & Co's portfolio in Q3 2026, its #1156 holding.
Davenport & Co first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 10 quarters since.
Davenport & Co's Axsome Therapeutics position peaked at $1.1M in Q4 2022.
185 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Davenport & Co's 13F filing for Q3 2026, filed 14 Oct 2026.